

# Resource Summary Report

Generated by [Kravitz](#) on Sep 19, 2026

## CD3-PerCP-Vio700, human

RRID:AB\_2659948

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-097-582, RRID:AB\_2659948

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2659948](http://antibodyregistry.org/AB_2659948)

**Proper Citation:** Miltenyi Biotec Cat# 130-097-582, RRID:AB\_2659948

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Discontinued: 8-2018; Target Distribution NK cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-132. (RRID:AB\_2725960).

**Antibody Name:** CD3-PerCP-Vio700, human

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** BW264/56

**Antibody ID:** AB\_2659948

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-097-582

**Record Creation Time:** 20231110T034401+0000

**Record Last Update:** 20260829T054112+0000

### Ratings and Alerts

No rating or validation information has been found for CD3-PerCP-Vio700, human.

**Warning:** Discontinued: 2021

Discontinued: 8-2018; Target Distribution NK cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-132. (RRID:AB\_2725960).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [Kravitz](#) .

Chen L, et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 49(3), 464.